Cargando…
Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer
BACKGROUND: Methylene blue as tracer used in sentinel lymph node biopsy (SLNB) have low detection rate and high false negative rate. Indocyanine green (ICG) can detect the flow of subcutaneous lymphatic vessels and the position of lymph nodes dynamically. This study sought to evaluate the efficacy o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547706/ https://www.ncbi.nlm.nih.gov/pubmed/36221275 http://dx.doi.org/10.21037/gs-22-434 |
_version_ | 1784805322690396160 |
---|---|
author | Xu, Yong Yuan, Songlin Chen, Mingtao Gong, Ke Liu, Youzhong Li, Shengyun Xiong, Fang Pan, Yuejun Cao, Jiyao Gong, Jia Luo, Na |
author_facet | Xu, Yong Yuan, Songlin Chen, Mingtao Gong, Ke Liu, Youzhong Li, Shengyun Xiong, Fang Pan, Yuejun Cao, Jiyao Gong, Jia Luo, Na |
author_sort | Xu, Yong |
collection | PubMed |
description | BACKGROUND: Methylene blue as tracer used in sentinel lymph node biopsy (SLNB) have low detection rate and high false negative rate. Indocyanine green (ICG) can detect the flow of subcutaneous lymphatic vessels and the position of lymph nodes dynamically. This study sought to evaluate the efficacy of ICG combined with methylene blue staining in SLNB of breast cancer. METHODS: One hundred and fifty-six early breast cancer patients treated at our hospital from July 2020 to May 2022 were enrolled in this study. SLNB was performed by ICG combined with methylene blue staining under the guidance of the fluorescent tracer navigation system FLI-10B. Standard axillary lymph node dissection (ALND) was performed in patients with sentinel lymph node (SLN) metastasis confirmed by intraoperative frozen pathology, while low ALND was performed in patients with negative SLNs. According to the staining condition, the SLNs were divided into: (I) the combined group (SLNs with methylene blue staining and/or ICG luminescence); (II) the methylene blue group (SLNs with methylene blue staining alone); and (III) the ICG group (SLNs with ICG luminescence alone). The detection rate, accuracy, sensitivity, and false negative rate of SLNB were compared among the 3 groups. RESULTS: A total of 592 SLNs were detected in the combined group (average 3.8 SLNs), yielding a detection rate of 97.4%; the accuracy, sensitivity, and false negative rates were 97.4%, 92.7%, and 7.3%. In the methylene blue group, 390 SLNs were detected (average 2.5 SLNs), yielding a detection rate of 84.6%; the accuracy, sensitivity, and false negative rates were 83.3%, 89.1%, and 10.9%. A total of 483 SLNs were detected in the ICG group (average 3.1 SLNs), the detection rate was 92.9%; the accuracy, sensitivity and false negative rates were 91.7%, 90.9%, and 9.1%. The average number of detected SLNs, detection rate and accuracy rate in the combined group were higher than those in the methylene blue group (P<0.05), and the accuracy rate of the combined group was higher than that of the ICG group (P<0.05). CONCLUSIONS: ICG combined with methylene blue staining is a promising and effective tracing strategy in the SLNB of breast cancer with high detection and accuracy rates. |
format | Online Article Text |
id | pubmed-9547706 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-95477062022-10-10 Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer Xu, Yong Yuan, Songlin Chen, Mingtao Gong, Ke Liu, Youzhong Li, Shengyun Xiong, Fang Pan, Yuejun Cao, Jiyao Gong, Jia Luo, Na Gland Surg Original Article BACKGROUND: Methylene blue as tracer used in sentinel lymph node biopsy (SLNB) have low detection rate and high false negative rate. Indocyanine green (ICG) can detect the flow of subcutaneous lymphatic vessels and the position of lymph nodes dynamically. This study sought to evaluate the efficacy of ICG combined with methylene blue staining in SLNB of breast cancer. METHODS: One hundred and fifty-six early breast cancer patients treated at our hospital from July 2020 to May 2022 were enrolled in this study. SLNB was performed by ICG combined with methylene blue staining under the guidance of the fluorescent tracer navigation system FLI-10B. Standard axillary lymph node dissection (ALND) was performed in patients with sentinel lymph node (SLN) metastasis confirmed by intraoperative frozen pathology, while low ALND was performed in patients with negative SLNs. According to the staining condition, the SLNs were divided into: (I) the combined group (SLNs with methylene blue staining and/or ICG luminescence); (II) the methylene blue group (SLNs with methylene blue staining alone); and (III) the ICG group (SLNs with ICG luminescence alone). The detection rate, accuracy, sensitivity, and false negative rate of SLNB were compared among the 3 groups. RESULTS: A total of 592 SLNs were detected in the combined group (average 3.8 SLNs), yielding a detection rate of 97.4%; the accuracy, sensitivity, and false negative rates were 97.4%, 92.7%, and 7.3%. In the methylene blue group, 390 SLNs were detected (average 2.5 SLNs), yielding a detection rate of 84.6%; the accuracy, sensitivity, and false negative rates were 83.3%, 89.1%, and 10.9%. A total of 483 SLNs were detected in the ICG group (average 3.1 SLNs), the detection rate was 92.9%; the accuracy, sensitivity and false negative rates were 91.7%, 90.9%, and 9.1%. The average number of detected SLNs, detection rate and accuracy rate in the combined group were higher than those in the methylene blue group (P<0.05), and the accuracy rate of the combined group was higher than that of the ICG group (P<0.05). CONCLUSIONS: ICG combined with methylene blue staining is a promising and effective tracing strategy in the SLNB of breast cancer with high detection and accuracy rates. AME Publishing Company 2022-09 /pmc/articles/PMC9547706/ /pubmed/36221275 http://dx.doi.org/10.21037/gs-22-434 Text en 2022 Gland Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Xu, Yong Yuan, Songlin Chen, Mingtao Gong, Ke Liu, Youzhong Li, Shengyun Xiong, Fang Pan, Yuejun Cao, Jiyao Gong, Jia Luo, Na Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer |
title | Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer |
title_full | Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer |
title_fullStr | Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer |
title_full_unstemmed | Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer |
title_short | Evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer |
title_sort | evaluation of indocyanine green combined with methylene blue staining in sentinel lymph node biopsy of breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547706/ https://www.ncbi.nlm.nih.gov/pubmed/36221275 http://dx.doi.org/10.21037/gs-22-434 |
work_keys_str_mv | AT xuyong evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT yuansonglin evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT chenmingtao evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT gongke evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT liuyouzhong evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT lishengyun evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT xiongfang evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT panyuejun evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT caojiyao evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT gongjia evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer AT luona evaluationofindocyaninegreencombinedwithmethylenebluestaininginsentinellymphnodebiopsyofbreastcancer |